A phase II trial of potency-sparing hormonal therapy [flutamide + finasteride] in patients with elevated serum PSA after radiation therapy or radical prostatectomy for prostate cancer.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Finasteride; Flutamide
- Indications Prostate cancer
- Focus Therapeutic Use
- 04 Jul 2016 Biomarkers information updated
- 21 Jun 2011 Planned end date (Jul 2017) added as reported by ClinicalTrials.gov.
- 21 Jun 2011 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov.